<DOC>
	<DOCNO>NCT00540592</DOCNO>
	<brief_summary>In order find formulation lead maximal increase immune response maintain acceptable safety profile , study design evaluate immunogenicity , safety reactogenicity different formulation GSK Biologicals ' influenza vaccine administer adult age 65 year old compare Fluarix .</brief_summary>
	<brief_title>Immunogenicity Safety Study Evaluate Different Formulations GSK Biologicals ' Influenza Vaccine GSK576389A</brief_title>
	<detailed_description>There 10 parallel group : 9 observer blind group subject 65 year old receive investigational vaccine Fluarix , 1 open group subject 18 40 year old receiving Fluarix . CMI response determine subset . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol enrol study . A male female age 1840 year old 65 year old time vaccination . Written inform consent obtain subject . Free acute aggravation health status establish clinical evaluation ( medical history medical history direct examination ) enter study . If subject female , must nonchildbearing potential childbearing potential , must practice adequate contraception 30 day prior vaccination , negative pregnancy test continue precaution 2 month completion vaccination series . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day prior vaccination , plan use study period . Administration license vaccine within 2 week ( inactivated vaccine ) 4 week ( live vaccine ) prior enrolment study . Planned administration vaccine foreseen study protocol entire study period . Planned administration influenza vaccine study vaccine entire study period . Vaccination influenza since January 2007 ( 2007/2008 2006/2007 influenza vaccine ) . Administration 14 day immunosuppressant immunemodifying drug within 6 month prior administration study vaccine . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination Hypersensitivity previous dose influenza vaccine . Allergy component vaccine . Acute ( active ) clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality . Acute disease time enrolment . ( Acute disease define presence moderate severe illness without fever . All vaccine administer person minor illness diarrhoea , mild upper respiratory infection without lowgrade febrile illness , i.e . axillary temperature &lt; 37.5ºC ( 99.5ºF ) . Administration immunoglobulins and/or blood product within three month precede first administration study vaccine plan administration study . Any medical condition IM injection contraindicate . Lactating female female planning become pregnant discontinue contraceptive precaution</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Influenza vaccine GSK576389A</keyword>
	<keyword>Influenza infection</keyword>
	<keyword>Fluarix</keyword>
</DOC>